Joanne Jeter, MD, MS

Medical Oncologist, Clinical Cancer Geneticist

City of Hope

Joanne Jeter, MD, MS (she/her) is a board-certified medical oncologist and clinical cancer geneticist. She started working at City of Hope on October 16, 2023, and is very excited about joining many of her friends in this prestigious group. Her medical school training was at the University of Texas-Houston Health Sciences Center. She subsequently completed her residency in Internal Medicine at the University of Alabama-Birmingham. While she was in her Medical Oncology fellowship program at the University of Michigan, she was fortunate to start working with Dr. Stephen Gruber's clinical cancer genetics program, and this has been her primary focus since that time. She has also earned a Master's degree in Clinical Trials Design and Statistical Analysis at the University of Michigan. Prior to her time at City of Hope, she was the Medical Director for the Family Cancer Assessment Clinic at Huntsman Cancer Institute at the University of Utah. She has also worked as a medical oncologist and clinical cancer geneticist at the University of Arizona and the Ohio State University.

Judy Garber, MD, MPH

Director, Center for Cancer Genetics and Prevention

Dana Farber Cancer Institute

Dr. Garber is the Director of the Cancer Genetics and Prevention Disease Center at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. Dr. Garber conducts research in clinical cancer genetics, with a special focus in the genetics of breast cancer. She has played a major role in the development of national guidelines in cancer genetics. She is also a leader in research into the characteristics and treatment of triple negative or basal-like breast cancer, the most common form in women with BRCA1 mutations. Her translational research focuses on the evaluation of novel agents targeting DNA repair defects in breast cancer, including PARP inhibitors for treatment and prevention of breast cancer and other BRCA-associated cancers.

 In 2011-2012, Dr. Garber was the President of American Association for Cancer Research (AACR), the largest organization of cancer researchers in the world. She is a member of the National Cancer Advisory Board and was recently elected to the Institute of Medicine.

Carol Fabian, MD

Director, Breast Cancer Prevention & Survivorship Centers

KU Breast Cancer Prevention Center

Dr. Carol Fabian is a breast medical oncologist, University Distinguished Professor, and holds the Morris Endowed Chair in Cancer Prevention at the University of Kansas Medical Center.  She received her medical degree from the University of Kansas in 1972, and fellowship in Medical Oncology at the University of Kansas in 1977.  She is board certified in both Internal Medicine and Medical Oncology.  She  has been on the faculty in the Division of Medical Oncology since 1977 and has served in multiple capacities including Medical Director of the Cancer Center, Founder and Director of the Breast Cancer Prevention and Survivorship Research Center, Leader or co-Leader of the Cancer Prevention Program, and Associate Director of Clinical Research in the NCI Designated Cancer Center.

Key:

Complete
Failed
Available
Locked
Clinical Management of Hereditary Breast Cancer
Open to view video.  |  67 minutes
Open to view video.  |  67 minutes • Review the tools for high-risk breast and ovarian cancer screening • Identify the role and efficacy of breast and ovarian cancer surgical risk reduction • Recognize the role of chemoprevention options for breast and ovarian cancer risk reduction • Use evidence-based guidelines to inform risk management recommendations for patients with pathogenic variants in high or moderate penetrance breast and ovarian cancer susceptibility genes • Apply individualized screening and risk management options and recommendations to case examples
HBOC Clinical Management and Precision Medicine: Evidence-based Updates, Part 1
Open to view video.  |  50 minutes
Open to view video.  |  50 minutes Review NCCN guidelines for high-risk cancer screening and management. Identify the methods and efficacy of breast and gynecologic screening tools. Identify the methods and efficacy of breast and ovarian surgical risk reduction. Understand the potential impact of cancer risk assessment and genetic testing related to surgical decision-making and timing. Recognize emerging role of targeted therapies for high-risk individuals (e.g., BRCA, PTEN, etc.).
HBOC Clinical Management and Precision Medicine: Evidence-based Updates, Part 2 Chemoprevention
Open to view video.  |  58 minutes
Open to view video.  |  58 minutes Review chemopreventive clinical trials pertinent to individuals at high risk for developing cancer. Apply these data appropriately to individuals at genetic versus empiric high risk. Describe chemoprevention studies currently open for enrollment.
Reminder: HBOC Risk Assessment Homework
Due Thursday
Due Thursday This assignment can be completed through the link emailed to you, please check your inbox and spam. Your emailed link is unique to you and should not be shared with others. Please submit BEFORE the Friday web session. Answers will be reviewed with Julie Culver this Friday. Once you have completed the assignment you can MARK AS COMPLETE
Quiz Week 5 - IC 25
4 Questions  |  Unlimited attempts  |  5/6 points to pass
4 Questions  |  Unlimited attempts  |  5/6 points to pass Select the appropriate response for each question. Correct responses will display after a passing score of 80% (6/7) is reached. Please retake the quiz until you pass.
Week 5 Distance Learning Evaluation
5 Questions
5 Questions Complete AFTER you have viewed the week's modules and attended the Friday web session. Please respond to the statements in this evaluation as they relate to your experiences with this week's Distance Learning Modules and Friday Web Conference Review session. This survey will take less than 3 minutes to complete.
Week 5 Friday Session Slides with Quiz Review
Open to download resource.
Open to download resource.
Week 5 Web Session Recording
Open to view video.  |   Closed captions available  |  93 minutes
Open to view video.  |   Closed captions available  |  93 minutes Friday, December 6, 2024. This recording is provided for review purposes only and viewing does not substitute attendance. DO NOT share, download, or save this recording. Recordings of future web sessions will be uploaded at the discretion of the Education team. Thank you.